Effects of NK1 antagonist treatment on BBB permeability to Evans blue and edema formation.

<p>Using Evan's blue (EB) (A) as a marker of BBB disruption treatment with both the NK1 antagonist Emend and dexamethasone resulted in a reduction of BBB permeability back to control levels (p = 0.0237). Similarly, NK1 antagonist and dexamethasone treatment resulted in a significant reduction of brain water content (B) compared to tumor inoculated vehicle treated mice (p = 0.0188). Brain water content n = 5 per group, EB n = 6 per group (*p<0.05 compared to shams for EB, *p<0.05 compared to vehicle for WWDW).